CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist ...

A live webcast of the presentation will be available via the Upcoming Events section of the Company’s investor relations website at https://ir.galecto.co/news-and-events/events. An archived replay ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The biggest challenge in training the next generation of respiratory therapists is getting them to engage in "critical ...

The following is a summary of “Role of glucocorticoid receptor expression in Chronic Chagas Cardiomyopathy: implications for ...

Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.

Inhibition of BRSK2 attenuated lung fibrosis in cellular and animal models, identifying it as a potential therapeutic target for IPF.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The peptide Palmitoyl-GHK (Pal-GHK) has garnered considerable attention in the scientific community due to its structural attributes and potential functional roles in biological research and cellular ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Building on clinical data from millions of individuals who received lipid-encapsulated mRNA vaccines, the FDA has issued new guidance that could facilitate a faster transition to first-in-human trials ...